Results 21 to 30 of about 9,108 (204)

Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells

eLife, 2018
Human immunodeficiency virus (HIV) infection is currently incurable, due to the persistence of latently infected cells. The ‘shock and kill’ approach to a cure proposes to eliminate this reservoir via transcriptional activation of latent proviruses ...
Emilie Battivelli, Matthew S Dahabieh, Mohamed Abdel-Mohsen, J Peter Svensson, Israel Tojal Da Silva, Lillian B Cohn, Andrea Gramatica, Steven Deeks, Warner C Greene, Satish K Pillai, Eric Verdin   +10 more
doaj   +1 more source

Coloring hidden viruses

eLife, 2018
An improved dual-color reporter reveals how the fate of latent HIV-1 depends on where it integrates in the human genome.
Marina Lusic
doaj   +1 more source

Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy

Cell Reports, 2019
Summary: Latent proviruses persist in central (TCM), transitional (TTM), and effector (TEM) memory cells. We measured the levels of cellular factors involved in HIV gene expression in these subsets.
Marion Pardons, Rémi Fromentin, Amélie Pagliuzza, Jean-Pierre Routy, Nicolas Chomont   +4 more
doaj   +1 more source

The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells

JCI Insight, 2023
IL-15 is under clinical investigation toward the goal of curing HIV infection because of its abilities to reverse HIV latency and enhance immune effector function. However, increased potency through combination with other agents may be needed.
Dennis C. Copertino Jr., Carissa S. Holmberg, Jared Weiler, Adam R. Ward, J. Natalie Howard, Callie Levinger, Alina P.S. Pang, Michael J. Corley, Friederike Dündar, Paul Zumbo, Doron Betel, Rajesh T. Gandhi, Deborah K. McMahon, Ronald J. Bosch, Noemi Linden, Bernard J. Macatangay, Joshua C. Cyktor, Joseph J. Eron, John W. Mellors, Colin Kovacs, Erika Benko, Alberto Bosque, R. Brad Jones, for the AIDS Clinical Trials Group (ACTG) A5321 Team   +23 more
doaj   +1 more source

Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo

Cell Reports Medicine, 2020
Summary: “Shock and kill” strategies focus on purging the latent HIV-1 reservoir by treating infected individuals with therapeutics that activate the latent virus and subsequently eliminating infected cells.
Lars Pache, Matthew D. Marsden, Peter Teriete, Alex J. Portillo, Dominik Heimann, Jocelyn T. Kim, Mohamed S.A. Soliman, Melanie Dimapasoc, Camille Carmona, Maria Celeridad, Adam M. Spivak, Vicente Planelles, Nicholas D.P. Cosford, Jerome A. Zack, Sumit K. Chanda   +14 more
doaj   +1 more source

Natural killer cells induce HIV-1 latency reversal after treatment with pan-caspase inhibitors

Frontiers in Immunology, 2022
The establishment of a latency reservoir is the major obstacle for a cure of HIV-1. The shock-and-kill strategy aims to reactivate HIV-1 replication in HIV -1 latently infected cells, exposing the HIV-1-infected cells to cytotoxic lymphocytes.
Joana Furtado Milão, Luca Love, George Gourgi, Lukas Derhaschnig, J. Peter Svensson, Anders Sönnerborg, Anders Sönnerborg, Robert van Domselaar   +7 more
doaj   +1 more source

CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T cells

iScience
Summary: HIV-1 latency is regulated by chromatin modifying enzymes, and histone deacetylase inhibitors (HDACi) cause reactivation of provirus expression.
Riley M. Horvath, Ivan Sadowski
doaj   +1 more source

The role of Tat in HIV latency and reactivation

Frontiers in Immunology
HIV persists during therapy due the existence of a latently infected reservoir in which viral gene expression is silenced. This reservoir thus represents the primary barrier to a cure for HIV.
David M. Margolis, Edward P. Browne
doaj   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Protocol for intracellular immunofluorescence measurements of latent HIV reactivation in a primary CD4+ T cell model

STAR Protocols
Summary: Investigating the molecular mechanisms of HIV latency reversal in a proper physiological context can only be done in primary cells. Here, we describe a primary T cell model of HIV latency and a reliable flow cytometry assay to measure latency ...
Uri Mbonye, Anna Agaponova, Muda Yang, Jonathan Karn   +3 more
doaj   +1 more source